RSV

The nation is entering an “unprecedented vaccine season,” with the availability of vaccines for three viruses responsible for the most hospitalizations among older adults, according to Omnicare pharmacists.

COVID-19 and respiratory syncytial virus cases are increasing, and the height of influenza season is on the horizon, but older adults and long-term care staff members are entering the first virus season...

The elderly — and all of us — deserve to know that the air we and our loved ones are breathing is safe and healthy.

The poll, however, reveals that once they are aware of the vaccine, about two-thirds of older adults are interested in receiving it.

Just 13% of respondents knew about the existence of an approved vaccine against RSV for older adults. Those educated on vaccine approval process or about potential severity of RSV may be more accepting.

Those adults considered most at risk have chronic heart or lung disease, a weakened immune system or live in a long-term care facility.

The panel called for “shared clinical decision-making” between doctors and patients and stopped short of recommending that all older adults get the shots.

The CDC is expected to meet later in the month to adopt vaccine recommendations for older Americans.

Arexvy was ~82% effective in preventing RSV-induced lower respiratory tract infections in adults aged 60 or more years.

The findings seen in phase 3 trial of adults aged 60 years and older receiving a single intramuscular injection of RSVpreF vaccine.